Bone marrow harvesting (BMH) was performed on 40 consecutive allogeneic or autologous donors using EMLA (eutectic mixture of local anaesthetics), local anaesthesia (LA) and patient-controlled analgesia with alfentanil (PCA-A). The effect of alkalinizing the LA solution on reducing pain during LA infiltration in the presence of EMLA was also investigated. EMLA 10 g with occlusive dressing was applied to the harvest sites at least 60 min before BMH. The PCA device was programmed to deliver an intravenous loading dose of 15 g/kg alfentanil, followed by a background alfentanil infusion of 0.05 g/kg/min. Demand dose was 4 g/kg and lockout time was 3 min. Donors were randomized to receive either alkalinized (n = 19) or non-alkalinized (n = 21) LA solution (lignocaine 1% with 1:100 000 adrenaline). While post-operative nausea and vomiting were the only side-effects, all donors in both groups reported satisfactory pain scores during LA infiltration and satisfactory overall intra-operative comfort scores. They completed BMH using either regimen successfully, found this technique acceptable and would recommend this form of anaesthesia to others. Alkalinizing the LA solution did not significantly improve the pain scores during LA infiltration in the presence of EMLA. In conclusion, BMH can be performed safely using EMLA, LA and PCA-A without major complications.
nancies and systemic involvement. 5 Our previous experience, as well as that of others, has shown that lignocaine 1% with 1:200 000 adrenaline produced significant pain during the initial skin infiltration in some donors. 1, 6 Various studies have demonstrated that adding a small amount of 8.4% sodium bicarbonate to the LA solution can significantly reduce such pain. 7, 8 In addition, a eutectic mixture of local anaesthetics (EMLA, Astra, Södertälje, Sweden) cream is also an effective cutaneous anaesthetic, 9, 10 although there is no previous experience reported in the literature on the combined use of EMLA and alkalinized LA in attenuating the pain associated with LA infiltration. Therefore, in an attempt to improve the comfort level of our donors, we conducted a study to investigate the clinical advantage of alkalinized LA in the presence of EMLA among donors undergoing posterior iliac crests BMH procedures using PCA-A. In addition, we measured serum lignocaine concentrations before, during and after BMH in some donors to determine if they remained below the recommended toxic concentrations.
Materials and methods
This prospective randomized, double-blind study was approved by the Ethics Committee of Singapore General Hospital and funded by the Department of Clinical Research, Ministry of Health, Singapore (Grant No. P001-FY95-96). Consecutive ASA (American Society of Anesthesiologists 11 ) class 1 or 2 adult in-patient donors of either sex undergoing allogeneic or autologous BMH were admitted into this study. Donors who refused to participate, had a psychiatric history or a history of allergy to any medication used in the protocol, or did not understand the use of PCA, were excluded from the study. All study donors were interviewed 1 day before the procedure by one of the investigators during which time the concept and use of PCA-A were explained to them in detail and written consent for the study obtained. They were assured that an alternative form of anaesthesia (ie GA or RA) would be instituted any time during BMH if they found themselves unduly uncomfortable, painful or anxious. All were fasted for at least 6 h before the procedures and not premedicated.
On the day of BMH, EMLA cream 5 g with occlusive dressing was applied by one of the investigators to each posterior iliac crest at least 60 min prior to the procedure. The donors were then randomized to receive either alkalin-ized LA solution (ALK-LA group) or normal saline-LA solution (NS-LA or control group) during BMH. These solutions were constituted by adding either 1 ml 8.4% sodium bicarbonate or 1 ml normal saline (NS) respectively to a 20 ml mixture of lignocaine 1% with 1:100 000 adrenaline (Xylocaine, Astra). They were prepared immediately before BMH by an anaesthetic nurse not directly involved in the study. The operators (haematologists or medical oncologists), the donors and the attending anaesthetists were blinded to the LA solution used. In the operating theatres bone marrow was aspirated from the posterior iliac crests using standard commercially available 11-gauge bone marrow biopsy needles.
Intravenous access was established under LA with a double lumen peripheral catheter (Twin-Cath, Arrow International, Reading, PA, USA). One intravenous port (18-gauge) was designated for infusion of fluids and blood products and the other (20-gauge) for alfentanil infusion. Blood samples for serum lignocaine concentration analysis were aspirated from a 22-gauge radial artery cannula inserted under LA, but this was omitted if the donor refused, or if difficulty was encountered in the placement of the arterial cannula. Instructions on the use of the PCA device were again repeated prior to the start of BMH. Donors would then adopt the prone position themselves, making sure that they were comfortable. Oxygen was administered continuously at 3 l/min via an end-tidal carbon dioxide (ET-CO 2 ) monitoring nasal cannula. Routine monitors included a non-invasive blood pressure device, electrocardiograph, pulse oximeter and capnograph. Sedation levels were recorded every 5 min according to a 4-point scale: (1) fully awake and co-operative; (2) mildly sedated, easily aroused verbally and co-operative; (3) excessively sedated, not easily aroused and not co-operative; (4) comatose, requiring naloxone for reversal. During and up to 6 h after BMH, 1000-1500 ml of crystalloid or colloid solutions (Plasmasteril; Fresnius, Bad Homburg, Germany, or Gelafundin; B Braun Pharmaceutical Industries, Penang, Malaysia), and 2-3 units of autologous or homologous blood were given to compensate for fasting and the aspirated marrow.
The Graseby 3300 PCA device (Graseby Medical, Watford, UK) was used for alfentanil administration. All intraoperative PCA events were recorded and downloaded with a Graseby DPU 411 Thermal Printer. Alfentanil (Rapifen, Janssen Pharmaceutica, Beerse, Belgium) 6 mg was diluted with normal saline to make a 30 ml solution resulting in a final alfentanil concentration of 200 g/ml. The PCA-A settings were based on our previous experience using LA and PCA-A for BMH procedures. 1 After obtaining baseline values for the haemodynamic, respiratory and sedation score, a single dose of intravenous ondansetron (Zofran; Glaxo Wellcome, Greenford, UK) 4 mg was administered followed by a loading dose of alfentanil 15 g/kg body weight at the time of skin preparation. Ondansetron was given to prevent perioperative nausea and vomiting. 12 Background alfentanil infusion was set at 0.05 g/kg/min, on-demand alfentanil doses were 4 g/kg, and lockout intervals were 3 min. Each donor was advised to use the PCA device whenever he or she needed additional pain relief. The operators then administered the LA solution (either ALK-LA or NS-LA) with the maximum dose of lignocaine being 7 mg/kg, while 3-5 min of waiting time was allowed for the lignocaine to take effect. The dose of lignocaine was not standardized because subcutaneous fat thickness was different among the donors, and the amount of lignocaine used also depended on operator technique, stem cell count, as well as the number of punctures required to harvest the desired amount of bone marrow. Arterial blood samples were obtained at fixed time intervals (baseline, 5, 10, 20, 30, 45 and 60 min after lignocaine administration) for measurement of the serum lignocaine concentrations using fluorescence polarization immunoassay (FPIA) technology (TDxFLX Lidocaine Assay System; Abbott Laboratory, Abbott Park, IL, USA). Arterial blood pressure, heart rate, respiratory rate, and arterial oxygen saturation (SaO 2 ) were recorded every 5 min throughout the procedure. The number of iliac crest punctures was recorded manually using a counter.
In the recovery room, all donors were monitored closely for at least 45 min. Sedation level, arterial blood pressure and SaO 2 were recorded every 5 min. Oral non-opioid analgesic agents were prescribed for post-operative pain relief in the wards. We interviewed all donors again 4-6 h after the procedure. They were requested to walk for a short distance and return to their beds unaided. Pain scores during local anaesthetic infiltration were then assessed at this time according to an 8-point scale (modified from Jamison RN et al): 13 (1) not noticeable; (2) just noticeable; (3) slight pain; (4) mild pain; (5) moderate pain; (6) severe pain; (7) intense pain; (8) excruciating pain. Pain scores р3 were considered as satisfactory. Overall intra-operative comfort levels were also assessed according to an 8-point scale: (1) comfortable, no pain at all; (2) very occasional slight pain, acceptable; (3) very occasional mild pain, acceptable; (4) frequent mild pain, situation can be improved; (5) frequent moderate pain, situation can be improved; (6) frequent severe pain, almost unbearable; (7) frequent intense pain, never again; (8) excruciating pain all the time, never again. Comfort scores р3 were considered as satisfactory. Scores of 4-6 were defined as unsatisfactory, and scores of 7-8 were defined as unacceptable pain requiring conversion to GA or RA. Acceptance of this technique by the individual donor was also evaluated at this time using a 4-point scale:
(1) highly acceptable; (2) acceptable; (3) disappointing; and (4) never again. In addition they were asked if they would recommend this form of anaesthesia to other donors, and about any complication they might have experienced after the procedures. Because of our limited experience in using EMLA, LA and PCA-A for BMH, we elected to observe the donors overnight during the study period. Twelve samples of the LA solution (six ALK-LA and six NS-LA) were analysed using a pH meter (HI 8418; Hanna Instruments, Singapore) to determine the pH of the prepared LA solution.
Statistical analysis
We defined acceptable pain scores during LA infiltration as р3. Scores of у4 were regarded as unacceptable. Before the commencement of the study, power analysis was performed. Based on our pilot study, we estimated that the rate of acceptable pain score was 90% in the control (NS-LA) group. Taking ␣ = 0.05 and power (␤) = 80%, a sample size of 14 in each group would be able to detect either a decline to 42% or an increase to 100% in the rate of acceptable pain score in the ALK-LA group. The t-test, MannWhitney test and 2 tests were used where appropriate to detect any statistically significant differences between the two groups in the variables studied. P Ͻ 0.05 was considered statistically significant.
Results
We studied 40 donors (20 allogeneic and 20 autologous), of which 19 belonged to the ALK-LA group and 21 belonged to the NS-LA group (control group). The demographic data of donors in both groups were comparable (Table 1) . Both groups were also comparable in terms of the duration of procedure, number of iliac crest punctures, volume of lignocaine used, volume of marrow aspirated, total dose of alfentanil administered, and number of good demands from PCA-A (Table 2 ). All donors tolerated the procedures well; none opted for GA or RA. They were mildly sedated and easily aroused verbally during BMH. The haematologists and medical oncologists involved were satisfied with this form of anaesthesia. Although none experienced any intra-operative cardiovascular, respiratory or other complications, post-operative nausea and vomiting seemed to be the main complaints among donors. One donor in the ALK-LA group (5.3%) and four donors in the control group (19%) complained of nausea; one donor in the ALK-LA group vomited (P = 0.26, no statistically significant difference). There were also no statistically sig- Table 2 The results of variables measured during BMH performed using EMLA, LA and PCA-A nificant differences between the two groups in terms of the infiltration pain score, overall intra-operative comfort score, and acceptance score (Table 3 ). All donors would recommend this form of anaesthesia to other donors. pH analysis of 12 samples of the prepared LA solution showed that at a mean temperature of 29.05 ± 0.44°C, the mean pH of the alkalinized LA solution was 7.19 ± 0.08. In contrast, at a mean temperature of 29.22 ± 0.19°C, the mean pH of the control LA solution was 3.14 ± 0.03. Serum lignocaine concentrations were measured in 22 donors. Figure 1 shows the mean lignocaine concentrations over the 60 min period after lignocaine infiltration.
Discussion
An ideal anaesthetic technique for BMH would be one that provides the greatest peri-operative donor satisfaction and comfort with the lowest risk of major life-threatening complications. Since LA may be safer than GA or RA, the option of performing BMH procedures under LA and PCA-A is attractive for donors. The types of pain encountered during BMH performed under LA are: (1) LA infiltration pain; (2) periosteal pain during multiple iliac crest punctures; and (3) pain related to bone marrow aspiration. Although we have previously demonstrated the feasibility of using LA and PCA-A for BMH, some donors did complain of pain during LA infiltration. 1 In our attempts to improve the comfort level of our donors, we investigated the combined use of EMLA, LA and PCA-A for BMH. In this study, EMLA cream alone had effectively reduced the pain associated with lignocaine infiltration to a highly acceptable level. More than 95% (18 out of 19 in the ALK-LA group and 20 out of 21 in the NS-LA group) of the donors reported infiltration pain scores of р2 (ie not noticeable or just noticeable), indicating excellent skin analgesia provided by EMLA at the harvesting sites. In addition, the technique of using EMLA, LA and PCA-A effectively reduced various pain stimuli at each point during the BMH. More than 80% (16 out of 19 in the ALK-LA group and 17 out of 21 in the NS-LA group) of the donors reported overall intra-operative pain scores of р2 (ie comfortable with no pain at all, or very occasional slight pain, acceptable). More than 80% (16 out of 19 in the ALK-LA group and 17 out of 21 in the NS-LA group) of our donors rated such a technique as highly acceptable, while the rest of the donors considered it as acceptable. All would recommend this anaesthetic technique to other donors. The 944  Table 3 The distribution of infiltration pain scores, overall intraoperative comfort scores, and acceptance scores among the donors Infiltration pain scores: 1 = not noticeable; 2 = just noticeable; 3 = slight pain; 4 = mild pain; 5 = moderate pain; 6 = severe pain; 7 = intense pain; 8 = excruciating pain. Overall intra-operative comfort scores: 1 = comfortable; 2 = very occasional slight pain; 3 = very occasional mild pain; 4 = frequent mild pain; 5 = frequent moderate pain; 6 = frequent severe pain; 7 = frequent intense pain; 8 = excruciating pain all the time. Acceptance scores: 1 = highly acceptable; 2 = acceptable; 3 = disappointing; 4 = never again. results indicate that BMH using EMLA, LA and PCA-A was well accepted.
EMLA is an acronym derived from eutectic mixture of local anaesthetics. The preparation contains the following ingredients in 1 ml of cream: 25 mg (2.5%) lignocaine, 25 mg (2.5%) prilocaine, arlatone (emulsifier), carbopol (thickener) and distilled water, with the pH adjusted to 9.4 using sodium hydroxide. 10 The result is a 5% cream containing a high concentration of the base form of the local anaesthetics in emulsion droplets, hence its ability to act as a cutaneous anaesthetic. 10 The maximal depth of analgesia (5 mm) has been observed for 30 min after a 90 min application, and during the 60 min period after a 120 min application.
14 Since EMLA has been reported to provide effective anaesthesia for venepuncture, subcutaneous injection, and even split skin grafting, 10, 15 we did not think a controlled trial comparing the efficacy of the EMLA cream against a control group was necessary in this study. Instead, we wanted to ascertain if the use of alkalinized LA solution is necessary in the presence of EMLA. Our results showed that the application of 5 g of EMLA to each harvest site for at least 60 min resulted in excellent skin anaesthesia, making the use of alkalinized LA solution unnecessary. There was very little systemic absorption as reflected by the measured baseline serum lignocaine concentrations in our donors (Figure 1 ). This is in accordance with the results of another study. 16 Side-effects of EMLA are mild, transient and well tolerated. They include blanching and erythema of the skin at the site of application secondary to the direct effects of the local anaesthetics on vascular smooth muscle. 10 EMLA is, however, not recommended in infants of less than 3 months of age because of the possibility of methaemoglobinaemia attributed to a metabolite of prilocaine. 10 Lignocaine 1% with 1:100 000 adrenaline was chosen for our study because it was the only lignocaine and adrenaline mixture available in our institution at the time of the study. At this concentration, 1 ml of the local anaesthetic would contain 10 g of adrenaline. Although lignocaine 1% with 1:200 000 adrenaline would be preferred as it reduces the adrenaline dose, we did not observe significant haemodynamic changes in our patients after subcutaneous infiltration of the LA mixture. The solution is acidic with a pH of 3.0-4.0, which makes it more soluble and stable and extends its shelf-life. It is this acidic environment that is believed to be responsible for the pain associated with its infiltration. 8 Addition of sodium bicarbonate to the lignocaine solution has been shown to reduce pain during infiltration. 7, 8 However, its use in this study did not improve infiltration pain scores. The most likely explanation is that the prior application of EMLA to all donors had created adequate surface anaesthesia. We did not compare serum lignocaine concentrations of the two groups because the amount of lignocaine given per donor was not standardized although it was limited to a maximum dose of 7 mg/kg. The mean lignocaine concentrations measured over a 60 min period were well below the toxic level of 4 g/ml (Figure 1) .
Alfentanil is often an opioid of choice for day-case patients because of its rapid (within 1 or 2 min), predictable onset and short duration of action, as well as its cardiovascular stability. [17] [18] [19] Its rapid onset of action provides immediate pain relief when required and its short duration of action prevents prolonged effects once the procedure is over. Alfentanil therefore offers good pain relief with a low incidence of major side-effects (eg hypotension or respiratory depression). In addition, it is metabolized into nonactive metabolites and has no residual narcotic effects after prolonged administration. 19 The availability of the opioid antagonist, naloxone, also improves its safety margin. As such, alfentanil was the analgesic chosen in our study although it probably resulted in post-operative nausea and vomiting in some of our donors. The routine use of a single dose of ondansetron may be considered an advantage in this respect. The use of PCA has overcome the limitations of physician-administered analgesia or sedation resulting in: (1) doses of analgesic delivered matching the donors' requirements and therefore avoiding under-or over-dosage; (2) no delay in analgesic administration when the needs arise; (3) increase in donor satisfaction because of donor autonomy. 20 PCA-alfentanil has also been employed successfully for other outpatient procedures. 21 There are limitations to the use of EMLA, LA and PCA-A for BMH. Uncooperative psychiatric donors, paediatric donors, and donors who do not understand the concept and use of the PCA device are not good candidates. Starting the BMH procedure at least 5 min after LA infiltration is mandatory to ensure better results. In situations of multiple harvest sites (ie more than just the posterior iliac crests) or prolonged BMH procedure, it may be necessary to continue BMH under GA. In conclusion, combined use of EMLA, LA and PCA-A is a safe, simple and effective technique for BMH. This technique can be offered as an alternative to GA or RA to marrow donors. The addition of sodium bicarbonate to the LA solution did not significantly improve the pain scores during LA infiltration in the presence of EMLA.
